EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Oral anti‐viral therapy for early COVID ‐19 infection in patients with haematological malignancies: A multicentre prospective cohort

Carla Minoia iD, Lucia Diella, Tommasina Perrone, Giacomo Loseto, Carmen Pelligrino, Immacolata Attolico iD, Crescenza Pasciolla, Valentina Totaro, Maria Stella De Candia, Vito Spada, Felice Clemente, Michele Camporeale und 5 weitere

British Journal of Haematology · 2023-09 · 202 (5) · 928-936

DOI: 10.1111/bjh.18895 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 31.05.2023. Verfasst von Carla Minoia und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High rates of lung failure have been reported in haematological patients after SARS‐CoV2 infection. An early administration of monoclonal antibodies or anti‐virals may improve the prognosis. Oral anti‐virals may have a wider use independently of the genetic variations of the virus. Prospective data on anti‐virals in haematological malignancies (HMs) are still lacking. Outpatients diagnosed with HM and early COVID‐19 infection were prospectively treated with the oral anti‐virals nirmatrelvir/ritonavir and molnupiravir. Incidence of lung failure, deaths and adverse events was analysed. Long‐term outcome at third month was evaluated. Eighty‐two outpatients were evaluable for the study objectives. All patients had been treated for their HM within 12 months. COVID‐19‐related lung failure was 23.1%. Active HM (aOR = 4.42; p = 0.038) and prolonged viral shedding (aOR = 1.04; p = 0.022) resulted independent predictors of severe infection. The vaccination with three to four doses (aOR = 0.02; p = 0.001) and with two doses (aOR = 0.06; p = 0.006) resulted protective. COVID‐19‐related deaths at 28 days were 6.1%. All‐cause mortality at 90‐day follow‐up was 13.4% ( n . 11) and included opportunistic infections and cardiovascular events. In conclusion, this approach reduced the incidence of lung failure and specific mortality compared to previous cohorts, but patients remain at high risk of further complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hematologic NeoplasmsHumansProspective StudiesRNA, ViralSARS-CoV-2Antiviral Agents

Stichwörter der Autor:innen

COVID-19SARS-CoV-2anti-viralcancerhaematological patientsmolnupiravirnirmatrelvir/ritonavir

Substanzen

RNA, ViralAntiviral Agents

Autor:innen und Institutionen

  • Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy.
  • Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.
  • Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.

ORCID-Profile: Carla Minoia, Immacolata Attolico

Zitieren

APA

Minoia, C., Diella, L., Perrone, T., Loseto, G., Pelligrino, C., Attolico, I., Pasciolla, C., Totaro, V., De Candia, M. S., Spada, V., Clemente, F., Camporeale, M., Di Gennaro, F., Guarini, A., Musto, P., Saracino, A., & Bavaro, D. F. (2023). Oral anti‐viral therapy for early COVID ‐19 infection in patients with haematological malignancies: A multicentre prospective cohort. British Journal of Haematology, 202(5), 928-936. https://doi.org/10.1111/bjh.18895

Vancouver

Minoia C, Diella L, Perrone T, Loseto G, Pelligrino C, Attolico I, et al. Oral anti‐viral therapy for early COVID ‐19 infection in patients with haematological malignancies: A multicentre prospective cohort. British Journal of Haematology. 2023;202(5):928-936. doi:10.1111/bjh.18895

BibTeX
@article{Minoia2023,
  author = {Minoia, Carla and Diella, Lucia and Perrone, Tommasina and Loseto, Giacomo and Pelligrino, Carmen and Attolico, Immacolata and Pasciolla, Crescenza and Totaro, Valentina and De Candia, Maria Stella and Spada, Vito and Clemente, Felice and Camporeale, Michele and Di Gennaro, Francesco and Guarini, Attilio and Musto, Pellegrino and Saracino, Annalisa and Bavaro, Davide Fiore},
  title = {Oral anti‐viral therapy for early COVID ‐19 infection in patients with haematological malignancies: A multicentre prospective cohort},
  journal = {British Journal of Haematology},
  year = {2023},
  volume = {202},
  number = {5},
  pages = {928--936},
  doi = {10.1111/bjh.18895}
}
Kostenlos starten →